Photo credit: researchers/THSTI
Date: 30 June 2020
Institution: Translational Health Science And Technology Institute (THSTI)
Digest: Researchers have now developed a monoclonal antibody against the SARS-CoV2. This antibody binds to the receptor-binding domain (RBD), a receptor that specifically recognizes ACE2 as its receptor and mediates the entry in host cells.
SARS-CoV-2 is now a global threat to lives. It has caused more infections and death that the outbreak happened around 2003. Scientists across the globe are working hard to counter this virus, be it detection or cure.
A team of Indian Scientists from DBT-THSTI’s Infection and Immunity Program, led by Dr. Rajesh Kumar, developed the human monoclonal antibody (mAb) against the receptor-binding domain (RBD) of SARS-CoV2. RBD is the primary target to block the virus.
The virus surface has spike protein, which contains this RBD domain. This RBD domain is responsible for the specific recognition of the ACE2 receptor on the host cells, and it mediates the entry of the virus into the cells.
The mAb developed by the researchers shows high affinity and specificity for the RBD of SAR-CoV2. The team has also developed different formats of this mAb – scFv, scFv-Fc, and IgG1.
Scientist says this platform will allow them for isolating the neutralizing antibodies, which might be helpful in COVID-19 treatment.
Furthermore, the availability of an extensive array of SARS-CoV2 specific monoclonal antibodies can help to design vaccines through structural vaccinology. This part of the research work has been submitted to a peer-reviewed journal for consideration.
The other co-investigators in the project are Drs. Shubbir Ahmad, Sweety Samal, Tripti Shrivastava, Hilal Ahmad, Shailendra Asthana, Chandresh Sharma, Shailendra Mani, and Adrash Chiranjivi.
The research is funded by DBT.